Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C17H20N4O2.2C2H6O4S |
| Molecular Weight | 564.63 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
OCCS(O)(=O)=O.OCCS(O)(=O)=O.NC(=N)C1=CC=C(OCCCOC2=CC=C(C=C2)C(N)=N)C=C1
InChI
InChIKey=WSOSYBUSMXEYDO-UHFFFAOYSA-N
InChI=1S/C17H20N4O2.2C2H6O4S/c18-16(19)12-2-6-14(7-3-12)22-10-1-11-23-15-8-4-13(5-9-15)17(20)21;2*3-1-2-7(4,5)6/h2-9H,1,10-11H2,(H3,18,19)(H3,20,21);2*3H,1-2H2,(H,4,5,6)
Propamidine, an aromatic diamidine compound, is widely used as an antimicrobial agent. Propamidine isethionate, the salt of propamidine with isethionic acid, is used in the treatment of Acanthamoeba infection. Diseases caused by Acanthamoeba include keratitis and granulomatous amoebic encephalitis.
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Treatment of experimental pneumocystosis: review of 7 years of experience and development of a new system for classifying antimicrobial drugs. | 1992 Sep |
|
| The accumulation of pentamidine and the toxic effects of the drug, its selected analogues and metabolites on isolated alveolar cells. | 1993 Jun 4 |
|
| DNA-binding activity and biological effects of aromatic polyamidines. | 1994 Feb 11 |
|
| Susceptibility of Encephalitozoon cuniculi to several drugs in vitro. | 1995 Jun |
|
| New drug developments for opportunistic infections in immunosuppressed patients: Pneumocystis carinii. | 1995 Nov 24 |
|
| 1,5-Bis(4-amidinophenoxy)pentane (pentamidine) is a potent inhibitor of [3H]idazoxan binding to imidazoline I2 binding sites. | 1998 Jul 17 |
|
| Anti-Pneumocystis activities of aromatic diamidoxime prodrugs. | 1998 Mar |
|
| Structure-in vitro activity relationships of pentamidine analogues and dication-substituted bis-benzimidazoles as new antifungal agents. | 1998 Oct |
|
| Encystation in Acanthamoeba castellanii: development of biocide resistance. | 2001 Jan-Feb |
|
| Persistence of a clone of methicillin-resistant Staphylococcus aureus in a burns unit. | 2001 Jun |
|
| Atypical presentation of Acanthamoeba keratitis. | 2001 Oct |
|
| [Acanthamoeba keratitis treated with propamidine and polyhexamethyl biguanide (PHMB)]. | 2002 Apr |
|
| Resistance of Acanthamoeba castellanii cysts to physical, chemical, and radiological conditions. | 2002 Jun |
|
| Progressive ulcerative keratitis related to the use of topical chlorhexidine gluconate (0.02%). | 2002 Mar |
|
| [Acanthamoeba keratitis, a possible dibromo propamidine isethionate resistance]. | 2002 May |
|
| Persistently culture positive acanthamoeba keratitis: in vivo resistance and in vitro sensitivity. | 2003 Aug |
|
| An atypical presentation of Acanthamoeba keratitis in a noncontact lens wearer. | 2003 Jan |
|
| A chromosomal location of the mupA gene in Staphylococcus aureus expressing high-level mupirocin resistance. | 2003 May |
|
| Persistent acanthamoeba keratitis in a non-contact lens wearer following exposure to bird seed dust. | 2005 Mar |
|
| Diagnosis and management of Acanthamoeba keratitis. | 2006 Aug |
|
| Acanthamoeba keratitis associated with misuse of daily disposable contact lenses. | 2006 Dec |
|
| Methicillin-resistant Staphylococcus aureus clones, Western Australia. | 2006 Feb |
|
| Antibacterial resistance and their genetic location in MRSA isolated in Kuwait hospitals, 1994-2004. | 2006 Nov 25 |
|
| Acanthamoeba keratitis due to Acanthamoeba genotype T4 in a non-contact-lens wearer in Turkey. | 2007 Jan |
|
| [Painless acanthamoeba keratitis]. | 2007 May |
|
| Good visual outcome after prompt treatment of acanthamoeba keratitis associated with overnight orthokeratology lens wear. | 2007 Nov |
|
| Acanthamoeba keratitis and contact lens wear. | 2007 Sep |
|
| Bilateral acanthamoeba keratitis. | 2008 Feb |
|
| Multicomponent reactions in fungicide research: the discovery of mandipropamid. | 2008 Feb 1 |
|
| Evaluation of Antioxidant and Wound Healing Effects of Alcoholic and Aqueous Extract of Ocimum sanctum Linn in Rats. | 2008 Mar |
|
| Rapidly progressive cataract and iris atrophy during treatment of Acanthamoeba keratitis. | 2008 May |
|
| Medical management approach to infectious keratitis. | 2008 May-Jun |
|
| Phenotypic and molecular characterization of Staphylococcus aureus isolates expressing low- and high-level mupirocin resistance in Nigeria and South Africa. | 2009 Jan 28 |
|
| The prevalence of antimicrobial resistance and carriage of virulence genes in Staphylococcus aureus isolated from food handlers in Kuwait City restaurants. | 2009 Jun 16 |
|
| Medical treatment for combined Fusarium and Acanthamoeba keratitis. | 2009 Mar |
|
| Major role for cysteine proteases during the early phase of Acanthamoeba castellanii encystment. | 2010 Apr |
|
| Bilateral Acanthamoeba keratitis in Synergeyes contact lens wear: clinical and confocal microscopy findings. | 2010 May |
|
| The dissemination of ST80-SCCmec-IV community-associated methicillin resistant Staphylococcus aureus clone in Kuwait hospitals. | 2010 Nov 4 |
|
| Propamidine decreas mitochondrial complex III activity of Botrytis cinerea. | 2010 Sep |
|
| First report of a mixed infection due to Acanthamoeba genotype T3 and Vahlkampfia in a cosmetic soft contact lens wearer in Iran. | 2010 Sep |
Patents
Sample Use Guides
1-2 drops in the affected eye 3-4 times daily, for not more than 1 week
Route of Administration:
Topical
There was compared the amoebicidal activity of the Brolene (propamidine isethionate, commercial product), propamidine isethionate and pentamidine isethionate (Pentam) in vitro against three different species of Acanthamoeba, and the drugs' corresponding biocompatibility with rabbit corneal epithelial and endothelial cell cultures. The results indicated that there were significant species differences in drug sensitivity. Propamidine (> 1,000 micrograms/ml) was clearly less effective than pentamidine (> 125 micrograms/ml) against A. castellanii, although equivalent potency (> 250 micrograms/ml) was observed against A. polyphaga. On the other hand, propamidine (> 31.25 micrograms/ml) was slightly more effective than pentamidine (> 62.5 micrograms/ml) against A. hatchetti.
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
FDA ORPHAN DRUG |
27288
Created by
admin on Fri Dec 15 15:58:42 GMT 2023 , Edited by admin on Fri Dec 15 15:58:42 GMT 2023
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
100000092322
Created by
admin on Fri Dec 15 15:58:42 GMT 2023 , Edited by admin on Fri Dec 15 15:58:42 GMT 2023
|
PRIMARY | |||
|
SUB04079MIG
Created by
admin on Fri Dec 15 15:58:42 GMT 2023 , Edited by admin on Fri Dec 15 15:58:42 GMT 2023
|
PRIMARY | |||
|
140-63-6
Created by
admin on Fri Dec 15 15:58:42 GMT 2023 , Edited by admin on Fri Dec 15 15:58:42 GMT 2023
|
PRIMARY | |||
|
87175
Created by
admin on Fri Dec 15 15:58:42 GMT 2023 , Edited by admin on Fri Dec 15 15:58:42 GMT 2023
|
PRIMARY | |||
|
34634
Created by
admin on Fri Dec 15 15:58:42 GMT 2023 , Edited by admin on Fri Dec 15 15:58:42 GMT 2023
|
PRIMARY | RxNorm | ||
|
7T9IJ84C42
Created by
admin on Fri Dec 15 15:58:42 GMT 2023 , Edited by admin on Fri Dec 15 15:58:42 GMT 2023
|
PRIMARY | |||
|
m9181
Created by
admin on Fri Dec 15 15:58:42 GMT 2023 , Edited by admin on Fri Dec 15 15:58:42 GMT 2023
|
PRIMARY | Merck Index | ||
|
C046651
Created by
admin on Fri Dec 15 15:58:42 GMT 2023 , Edited by admin on Fri Dec 15 15:58:42 GMT 2023
|
PRIMARY | |||
|
205-423-6
Created by
admin on Fri Dec 15 15:58:42 GMT 2023 , Edited by admin on Fri Dec 15 15:58:42 GMT 2023
|
PRIMARY | |||
|
DTXSID50161211
Created by
admin on Fri Dec 15 15:58:42 GMT 2023 , Edited by admin on Fri Dec 15 15:58:42 GMT 2023
|
PRIMARY | |||
|
Propamidine isethionate
Created by
admin on Fri Dec 15 15:58:42 GMT 2023 , Edited by admin on Fri Dec 15 15:58:42 GMT 2023
|
PRIMARY | |||
|
67413
Created by
admin on Fri Dec 15 15:58:42 GMT 2023 , Edited by admin on Fri Dec 15 15:58:42 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
PARENT (SALT/SOLVATE)
SUBSTANCE RECORD
